Workforce

Scoop: Forma axes discovery biology team as part of a broader reorganization

/>

by — on
Updated:

We just got tipped off about layoffs at Forma Therapeutics yesterday. Staffers tell us that 25 people in discovery biology got the ax, with execs attributing the cuts to issues involving their pact with Celgene. CEO Steve Tregay confirmed that there have been cuts, adding that they are part of a broader reorganization that is claiming 61 jobs at the company.

But Tregay declined to say anything about the Celgene relationship, which is a cornerstone of the Watertown, MA-based company.

According to Steve Tregay:

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,300+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription
GMP Biomanufacturing Operator
Aldevron Fargo, ND
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA
Visit Endpoints Careers ->